Experimental group:vaccination

4 trials

Sponsors

Jiangsu Provincial Center For Disease Control and Prevention (Public Health Research Institute of Jiangsu Province), Hubei Provincial Center for Disease Control and Prevention

Conditions

Invasive and non-invasive pneumococcal disease caused by 23 Streptococcus pneumoniae infectionsNovel Coronavirus Pneumonia (COVID-19)Novel coronavirus pneumonia (COVID-19)

Phase 1

A Phase I Clinical Trial of Influenza virus Vector COVID-19 Vaccine for intranasal Spray (DelNS1-2019-nCoV-RBD-OPT1)

Active, not recruitingChiCTR2000037782

Jiangsu Provincial Center For Disease Control and Prevention (Public Health Research Institute of Jiangsu Province)Novel Coronavirus Pneumonia (COVID-19)

Start: 2020-09-01Updated: 2020-11-09

Phase 4

Post-Marketing clinical study of inactivated novel coronavirus vaccine (Vero cells): Evaluation of the immunogenicity and safety of people infected with human immunodeficiency virus (HIV)

RecruitingChiCTR2100054393

Hubei Provincial Center for Disease Control and PreventionNovel coronavirus pneumonia (COVID-19)

Start: 2021-08-30Updated: 2022-11-20

Post-marketing clinical study of novel coronavirus inactivated vaccine (Vero cells): evaluation of immunogenicity and safety in elderly people with chronic bronchitis and chronic obstructive pulmonary disease

RecruitingChiCTR2100054474

Hubei Provincial Center for Disease Control and PreventionNovel Coronavirus Pneumonia (COVID-19)

Start: 2021-08-30Updated: 2022-11-20

Phase IV clinical trial of 23-valent pneumococcal polysaccharide vaccine

Active, not recruitingChiCTR2200056827

Hubei Provincial Center for Disease Control and PreventionInvasive and non-invasive pneumococcal disease caused by 23 Streptococcus pneumoniae infections

Start: 2022-02-08Updated: 2023-09-11

Related Papers

Safety and immunogenicity of a live-attenuated influenza virus vector-based intranasal SARS-CoV-2 vaccine in adults: randomised, double-blind, placebo-controlled, phase 1 and 2 trials.

2022-05-2698 citations